
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. demonstrates a promising outlook due to its advantageous position in the market for gastroesophageal reflux disease diagnostics, particularly with its leading products, EsoCheck and EsoGuard. The company is making strides with Medicare, indicating that favorable coverage is likely to be announced, which could enhance revenue potential and market penetration. Additionally, Lucid's first mover advantage with EsoGuard and its superior testing capabilities position it as an attractive acquisition target, signifying strong long-term growth prospects.
Bears say
Lucid Diagnostics Inc reported a pro forma net loss of $9.9 million, translating to an earnings per share (EPS) of $(0.10), which was worse than both the company's estimates and market consensus. The company's performance in processing EsoGuard tests significantly declined, with only 2,756 tests conducted in Q2, marking a downward trend from previous quarters and raising concerns about demand and market traction. Additionally, various risks, including liquidity issues, regulatory approvals, and competition, further contribute to the negative outlook for the stock, indicating challenges in achieving sustainable growth and profitability.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares